The expert committee of Drug Controller General of India has recommended the restricted emergency usage of coronavirus vaccine, ‘Covaxin’. The candidate vaccine was jointly developed by Bharat Biotech, Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
The indigenous vaccine was developed at Bharat Biotech’s dedicated BSL-3 facility in Hyderabad.
DCGI subject expert committee today reviewed the application of emergency use authorisation of Covaxin and gave it the green signal.
The Drug Controller General of India will be taking the final call on the approval of the vaccine once the expert committee provides them with relevant information and data.
Incidentally, Oxford-AstraZeneca vaccine, manufactured by the Serum Institute of India was also cleared by the specially appointed expert committee yesterday.
Both the vaccine recommendations will be sent to DCGI for approval.
